TS
ONC

Thomas Steyer’s BeOne Medicines Ltd ONC Stock Holding History

Thomas Steyer’s Portfolio ONC Stock Details ONC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,100
Closed -$327K – 191
2026
Q1 		$327K Hold
1,100
– – ﹤0.01% 116
2025
Q4 		$334K Hold
1,100
– – ﹤0.01% 106
2025
Q3 		$375K Hold
1,100
– – ﹤0.01% 97
2025
Q2 		$266K Hold
1,100
– – ﹤0.01% 109
2025
Q1 		$299K Hold
1,100
– – ﹤0.01% 108
2024
Q4 		$203K Hold
1,100
– – ﹤0.01% 129
2024
Q3 		$247K Buy
+1,100
New +$198K ﹤0.01% 128

Other funds holding ONC

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Thomas Steyer's ONC Position: Q2 2026 in Review

Thomas Steyer sold out of BeOne Medicines Ltd (ONC) in Q2 2026, closing a stake of 1,100 shares — an estimated $327K sold.

Thomas Steyer first reported a position in ONC in Q3 2024 and held it in 7 quarters. The position peaked at $375K in Q3 2025. 282 funds tracked by Wall St. Rank hold ONC as of Q2 2026.

  • Thomas Steyer reported no remaining BeOne Medicines Ltd position as of Q2 2026 after selling out during the quarter.
  • Thomas Steyer sold 1,100 BeOne Medicines Ltd shares in Q2 2026, an estimated $327K.
  • Thomas Steyer first reported a position in BeOne Medicines Ltd in Q3 2024 and held it in 7 quarters.
  • Thomas Steyer's BeOne Medicines Ltd position peaked at $375K in Q3 2025.
  • 282 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q2 2026.

Based on Farallon Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.